In Billing
Nov 14th, 2011
Effective June 30, 2011, the Centers for Medicare & Medicaid Services (CMS) will cover autologous cellular immunotherapy treatment for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer. Sipuleucel-T (PROVENGE®) is the first immunotherapy for prostate cancer to receive approval by the U.S. Food and Drug Administra...
Jul 15th, 2011
A final decision memo issued on June 30 by the Centers for Medicare & Medicaid Services (CMS) provides Medicare patients with metastatic prostate cancer immediate access to a new treatment, and new hope. Autologous cellular immunotherapy, known clinically as sipuleucel-T, stimulates “the body’s natural defenses (such as the white blood cells called dendritic cells, T-lymphocytes ...
In Billing
Jun 10th, 2011
The July 1 update of the Ambulatory Surgical Center (ASC) payment system brings changes to the ASC rates, payment indicators, and separately paid drugs and biologicals, as announced by the Centers for Medicare & Medicaid Services (CMS) in a transmittal released June 3. Notable changes include the addition of six, separately payable Category III CPT® ...
In Billing
May 31st, 2011
Updated payment files for the Medicare Physician Fee Schedule (MPFS) were released to contractors May 20. The files include several changes to HCPCS Level II and CPT® code descriptors and payment indicators. The list of Medicare-covered codes also grew. Medicare contractors were instructed to implement the updated payment files by July 5. Included in the updated payment ...
In CMS
May 13th, 2011
The July 1 quarterly HCPCS Level II update includes a handful of important drug/biological code changes. Effective July 1, HCPCS Level II code J7184 will be directly replaced with Q2041 Injection, Von Willebrand factor complex (human), Wilate, per 100 IU VWF RCo, which describes Wilate® for intravenous injection for spontaneous or trauma-induced bleeding in patients ...